Prosecution Insights
Last updated: November 04, 2026
Application No. 19/121,446

SURFACE-DISPLAY OVEREXPRESSION TECHNIQUE BY USING LIPOPROTEIN PrsA EXPRESSION SYSTEM

Non-Final OA §112
Filed
Apr 16, 2025
Priority
Oct 17, 2022 — RE 10-2022-0133553 +1 more
Examiner
GRASER, JENNIFER E
Art Unit
1645
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Future And Tech Co.
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
10m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
810 granted / 1054 resolved
+16.9% vs TC avg
Strong +23% interview lift
Without
With
+23.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
52 currently pending
Career history
1105
Total Applications
across all art units

Statute-Specific Performance

§101
6.0%
-34.0% vs TC avg
§103
26.4%
-13.6% vs TC avg
§102
16.4%
-23.6% vs TC avg
§112
39.6%
-0.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1054 resolved cases

Office Action

§112
DETAILED ACTION Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1 and 5-16 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 broadly recites the amino acid sequence of PrsA consists of the amino acid sequence of SEQ ID NO: 2 or “its variant” and it is unclear how the polypeptide ‘varies’ or what the ‘variant’ sequence comprises and if the variant is of function alone or sequence/structure alone or both. The structures of the variants are unclear so the metes and bounds of the invention are not readily understood. While the specification can be used to provide definitive support, the claims are not read in a vacuum. Rather, the claim must be definite and complete in and of itself. Limitations from the specification will not be read into the claims. Paragraph [35] of the specification recites that the scope of the PrsA according to the present invention includes a protein having an amino acid sequence represented by SEQ ID No. 2 and functional equivalents of the protein. The "functional equivalents" refer to proteins that have at least 30%, preferably, 40%, and more preferably, 50% sequence homology with the amino acid sequence represented by SEQ ID No. 2 as a result of addition, substitution, or deletion of amino acids, and exhibit substantially the same physiological activity as the protein represented by SEQ ID No. 2. The "substantially the same physiological activity" refers to the activity of displaying a target protein on the cell surface. It is unclear if these “functional equivalents” are the same as the more general “variants” claimed. The claims as they stand are incomplete and fail to provide adequate structural properties to allow one to identify what is being claimed. Appropriate clarification and/or correction is required. Claim 16 is vague and indefinite because it is unclear if the “antigen displayed on its surface” is the same thing as the “target protein” from claim 9 which is displayed on the microorganism’s surface. Appropriate clarification and/or correction is required. Claim Rejections - 35 USC § 112-Written Description The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1 and 5-16 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The claims recite, for example: 1. (original) A recombinant vector for the cell surface display of a target protein in which a polynucleotide encoding PrsA consisting of the amino acid sequence of SEQ ID No. 2 or its variant and a gene encoding a target protein are sequentially linked downstream of a PrsA promoter consisting of the nucleotide sequence of SEQ ID No. 3. 9. (original) A method of preparing a microorganism with a target protein displayed on its cell surface, comprising: culturing the transformed microorganism of claim 6 to display a target protein on the cell surface; and harvesting the microorganism with the target protein displayed on its cell surface. 11. (original) A microorganism with a target protein displayed on its cell surface prepared by the method of claim 9. To fulfill the written description requirements set forth under 35 USC § 112, first paragraph, the specification must describe at least a substantial number of the members of the claimed genus, or alternatively describe a representative member of the claimed genus, which shares a particularly defining feature common to at least a substantial number of the members of the claimed genus, which would enable the skilled artisan to immediately recognize and distinguish its members from others, so as to reasonably convey to the skilled artisan that Applicant has possession the claimed invention. Applicants have not described the genus of claimed nicotinamide nucleotide transhydrogenase proteins/genes such that the specification might reasonably convey to the skilled artisan that Applicants had possession of the claimed invention at the time the application was filed. The specification teaches variant sequences as recited in instant claims 2-4, but the use of any “variant” as recited in claim 1 does not have adequate written support. Additionally, the use of any microorganism, e.g., viruses, fungi, etc. do not also have adequate written support. With the written description of a genus, merely drawing a fence around a perceived genus is not a description of the genus. One needs to show that one has truly invented the genus, i.e., that one has conceived and described sufficient representative species encompassing the breadth of the genus. Otherwise, one has only a research plan, leaving it to others to explore the unknown contours of the claimed genus. See Ariad, 598 F.3d at 1353 (The written description requirement guards against claims that "merely recite a description of the problem to be solved while claiming all solutions to it and . . . cover any compound later actually invented and determined to fall within the claim's functional boundaries."). Abbvie Deutschland GmbH & Co. v. Janssen Biotech, Inc., 759 F.3d 1285, 1300, 111 U.S.P.Q.2d 1780, 1790, 2014 BL 183329, 12 (Fed. Cir. 2014). To fulfill the written description requirements set forth under 35 USC § 112, first paragraph, the specification must describe at least a substantial number of the members of the claimed genus, or alternatively describe a representative member of the claimed genus, which shares a particularly defining feature common to at least a substantial number of the members of the claimed genus, which would enable the skilled artisan to immediately recognize and distinguish its members from others, so as to reasonably convey to the skilled artisan that Applicant has possession the claimed invention. Applicants have not described the genus of claimed variants or transformed microorganisms such that the specification might reasonably convey to the skilled artisan that Applicants had possession of the claimed invention at the time the application was filed. Paragraph [50] recites: In the present invention, the microorganism is preferably lactic acid bacteria, and more preferably, lactic acid bacteria of the genus Lactobacillus, but the present invention is not limited thereto. The examples in the specification use a Lactobacillus paracasei strain. Paragraph [10] teaches that the reporter protein when used in a vector was displayed on the cell surface in all lactic acid bacteria transformed with a vector containing the coding sequence of the PrsA protein or its variants as defined in claims 2-4. The specification does not provide adequate written support for a host cell that uses the claimed vector, other than a bacterium. In transmembrane anchor proteins belonging to the general membrane protein types of Gram-positive and Gram-negative bacteria, 20 to 30 amino acids at the N-terminus or C- terminus, which are composed of hydrophobic amino acids, are inserted into the cell membrane in an alpha-helix structure to form an anchor, which has a limitation in that they cannot be displayed in large quantities because they significantly affect the rigidity of the membrane when being displayed in large quantities on the cell membrane. The second type, which is a lipoprotein anchor, is present on the cell surface by a mechanism in which the -SH group of a cysteine residue present immediately behind a secretion signal is covalently bonded to the carbon of the glycerin head of a lipid, which is a cell membrane component, and anchored to the cell membrane. Unlike the above-described transmembrane anchor that is inserted into the cell membrane, the lipoprotein anchor hangs on the lipid bilayer without affecting the rigidity of the membrane. Thus, it has the great advantage of being able to be displayed in large quantities on the cell surface. Further, Paragraph [35] recites: [35] The scope of the PrsA according to the present invention includes a protein having an amino acid sequence represented by SEQ ID No. 2 and functional equivalents of the protein. The "functional equivalents" refer to proteins that have at least 30%, preferably, 40%, and more preferably, 50% sequence homology with the amino acid sequence represented by SEQ ID No. 2 as a result of addition, substitution, or deletion of amino acids, and exhibit substantially the same physiological activity as the protein represented by SEQ ID No. 2. The "substantially the same physiological activity" refers to the activity of displaying a target protein on the cell surface. There is adequate written description for the breadth of these variants. The purpose of the "written description" requirement is broader than tomerely explain how to "make and use"; the applicant must convey with reasonableclarity to those skilled in the art that, as of the filing date sought, he or she was inpossession of the invention. The invention is, for purposes of the "writtendescription" inquiry, whatever is now claimed. See Vas-Cath, Inc. v. Mahurkar,935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Federal Circuit, 1991).Furthermore, the written description provision of 35 USC § 112 is severable fromits enablement provision; and adequate written description requires more than amere statement that it is part of the invention and reference to a potential methodfor isolating it. The nucleic acid itself is required. See Fiers v. Revel, 25 USPQ2d 1601, 1606 (CAFC 1993) and Amgen Inc. V. Chugai Pharmaceutical Co. Ltd., 18 USPQ2d 1016. Possession may be shown in a variety of ways including description of an actual reduction to practice, or by showing the invention was 'ready for patenting' such as by disclosure of drawings or structural chemical formulas that show that the invention was complete, or by describing distinguishing identifying characteristics sufficient to show that the applicant was in possession of the claimed invention. Moreover, because the claims encompass a genus of variant species, an adequate written description of the claimed invention must include sufficient description of at least a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics sufficient to show that Applicant was in possession of the claimed genus. However, factual evidence of an actual reduction to practice has not been disclosed by Applicant in the specification; nor has Applicant shown the invention was "ready for patenting" by disclosure of drawings or structural chemical formulas that show that the invention was complete; nor has Applicant described distinguishing identifying characteristics sufficient to show that Applicant were in possession of the claimed invention at the time the application was filed. For inventions in an unpredictable art, adequate written description of a genus which embraces widely variant species cannot be achieved by disclosing only one species within the genus'" (Id. at 1106); accordingly, it follows that an adequate written description of a genus cannot be achieved in the absence of a disclosure of at least one species within the genus. It is noted that MPEP 2111.01 states that "[d]uring examination, the claims must be interpreted as broadly as their terms reasonably allow." The Court of Appeals for the Federal Circuit has recently held that a "written description of an invention involving a chemical genus, like a description of a chemical species, 'requires a precise definition, such as by structure, formula [or] chemical name,' of the claimed subject matter sufficient to distinguish it from other materials." University of California v. Eli Lilly and Co., 1997 U.S. App. LEXIS 18221, at *23, quoting Fires v. Revel, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993). To fully describe a genus of genetic material, which is a chemical compound, applicants must (1) fully describe at least one species of the claimed genus sufficient to represent said genus whereby a skilled artisan, in view of the prior art, could predict the structure of other species encompassed by the claimed genus and (2) identify the common characteristics of the claimed molecules, e.g., structure, physical and/or chemical characteristics, functional characteristics when coupled with a known or disclosed correlation between function and structure, or a combination of these (paraphrased from Enzo Biochemical). University of Rochester v. G.D. Searle & Co. (69 USPQ2d 1886 (2004)) specifically points to the applicability of both Lilly and Enzo Biochemical to methods of using products, wherein said products lack adequate written description. While in University of Rochester v. G.D. Searle & Co. the methods were held to lack written description because not a single example of the product used in the claimed methods was described, the same analysis applies wherein the product, used in the claimed methods, must have adequate written description (see Enzo paraphrased above). In the instant case, there is no structure associated with function with regard to the members of a genus of any variants, with the added function of displaying a target protein. The specification does not describe the structure for a representative number of genes from the Genus, with the required functionality in the claim. An argument can be made that the recited genus of polypeptides is adequately described by the disclosure of the structure of PrsA of SEQ ID NO: 2, or said genes obtained any genus of Corynebacterium and one could use structural homology to isolate those genes encoding polypeptides and the encoding polynucleotides recited in the claims. However, as described below, the art clearly teaches the "Practical Limits of Function Prediction": Devos et al., (Proteins: Structure, Function and Genetics, 2000, Vol. 41: 98-107), teach that the results obtained by analyzing a significant number of true sequence similarities, derived directly from structural alignments, point to the complexity of function prediction. Different aspects of protein function, including (i) enzymatic function classification, (ii) functional annotations in the form of key words, (iii) classes of cellular function, and conservation of binding sites can only be reliably transferred between similar sequences to a modest degree. The reason for this difficulty is a combination of the unavoidable database inaccuracies and plasticity of proteins (Abstract, page 98) and the analysis poses interesting questions about the reliability of current function prediction exercises and the intrinsic limitation of protein function prediction (Column 1, paragraph 3, page 99) and conclude that "Despite widespread use of database searching techniques followed by function inference as standard procedures in Bioinformatics, the results presented here illustrate that transfer of function between similar sequences involves more difficulties than commonly believed. Our data show that even true pair-wise sequence relations, identified by their structural similarity, correspond in many cases to different functions (column 2, paragraph 2, and page 105).Whisstock et al., (Quarterly Reviews of Biophysics 2003, Vol. 36 (3): 307-340) also highlight the difficulties associated with "Prediction of protein function from protein sequence and structure": "To reason from sequence and structure to function is to step onto much shakier ground", closely related proteins can change function, either through divergence to a related function or by recruitment for a very different function, in such cases, assignment of function on the basis of homology, in the absence of direct experimental evidence, will give the wrong answer (page 309, paragraph 4), it is difficult to state criteria for successful prediction of function, since function is in principle a fuzzy concept. Given three sequences, it is possible to decide which of the three possible pairs is most closely related. Given three structures, methods are also available to measure and compare similarity of the pairs. However, in many cases, given three protein functions, it would be more difficult to choose the pair with most similar function, although it is possible to define metrics for quantitative comparisons of different protein sequences and structures, this is more difficult for proteins of different functions (page 312, paragraph 5), in families of closely related proteins, mutations usually conserve function but modulate specificity i.e., mutations tend to leave the backbone conformation of the pocket unchanged but to affect the shape and charge of its lining, altering specificity (page 313, paragraph 4), although the hope is that highly similar proteins will share similar functions, substitutions of a single, critically placed amino acid in an active-site residue may be sufficient to alter a protein's role fundamentally (page 323, paragraph 1). C. This finding is reinforced in the following scientific teachings for specific proteins in the art that suggest, even highly structurally homologous polypeptides do not necessarily share the same function, and many functionally similar proteins will have little or no structural homology to disclosed proteins. For example, proteins having similar structure have different activities (structure does not always correlate to function); Witowski et al., (Biochemistry 38:11643-11650, 1999) teaches that one conservative amino acid substitution transforms a beta -ketoacyl synthase into a malonyl decarboxylase and completely eliminates beta-ketoacyl synthase activity. The art also teaches that functionally similar molecules have different structures; Kisselev L., (Structure, 2002, Vol. 10: 8-9) teach that polypeptide release factors in prokaryotes and eukaryotes have same function but different structures. Because the art is unpredictable and the scope of the claim includes numerous structural variants and the genus is highly variant because a significant number of structural differences between genus members is permitted. The specification does not describe any members of the claimed genus by complete structure. One of skill in the art would reasonably conclude that the disclosure fails to provide a representative number of species to describe the genus, and thus, that the applicant was not in possession of the claimed genus. The claimed subject matter is not supported by an adequate written description because a representative number of species has not been described. There are no drawings or structural formulas disclosed of any of thesefragments or variants of the claimed polynucleotides/polypeptides (other than the variants recited in claims 2-4). There is no teaching in thespecification regarding which 30, 50%, etc. of the structure can be varied and still produce a polypeptide which has the same function. Although the disclosure of SEQ ID NOs: 2 combined with the knowledge in the art, may put one in possession of peptides that are at least 30%, 40% and preferably 50% identical to SEQ ID NO: 2, the level of skill and knowledge in the art is such that one of ordinary skill would not be able to identify without further testing which of those peptides would have the required functional activities. Based on the lack of knowledge and predictability in the art, those of ordinary skill in the art would not conclude that the applicant was in possession of the claimed genus of variants of a PrsA consisting of the amino acid sequence of SEQ ID NO: 2. As stated above, no information is provided which would indicate that Applicants had the possession of the claimed genus of polypeptides and the encoding polynucleotides, and with the recited function when used in a host cell of any microorganism. The claimed genera of has widely variable structures and associated functions. As it is discussed above, a minor changes in structure may result in changes affecting function, since, the specification provided no additional information (species/variant/mutant) correlating structure with function, one skilled in the art cannot reasonably conclude that applicant had possession of the claimed invention at the time the instant application was filed. Furthermore, "Possession may not be shown by merely describing how to obtain possession of members of the claimed ,genus or how to identify their common structural features" (See University of Rochester, 358 F.3d at 927, 69 USPQ2d at 1895). A definition by function, as we have previously indicated, does not suffice to define the genus because it is only an indication of what the .gene does (function), rather what it is (structure), see University of California v. Eli Lilly & Co., 43 USPQ2d 1938, thus above claims lack adequate written description. Applicant is referred to the revised guidelines concerning compliance with the written description requirement of U.S.C. 112, first paragraph, published in the Official Gazette and also available at www.uspto.gov Claim Rejections - 35 USC § 112-Enablement The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1 and 5-16 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for: A recombinant vector for the cell surface display of a target protein in which a polynucleotide encoding PrsA consisting of the amino acid sequence of SEQ ID No. 2 and a gene encoding a target protein are sequentially linked downstream of a PrsA promoter consisting of the nucleotide sequence of SEQ ID No. 3; And also a recombinant vector of claim 1 comprising a variant of PrsA, wherein residues 162 to 166 of the amino acid sequence of SEQ ID No. 2 are deleted; or wherein, in the variant of PrsA, in which residues 281 to 303 of the amino acid sequence of SEQ ID No. 2 are deleted; or the recombinant vector comprising a variant of PrsA, in which residues 162 to 166 and residues 281 to 303 of the amino acid sequence of SEQ ID No. 2 are deleted. And bacteria cells transformed with said recombinant vectors; does not reasonably provide enablement for the full breadth of the claims. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims. The specification states that substitutions, additions, or deletions, may be made to the defined sequences; however, the specification provides no guidance as which amino acids may be changed, with the exception of the variants recited in instant claims 2-4, without causing a detrimental effect to the PrsA polypeptide and with the added functional requirement. Paragraph [35] recites: [35] The scope of the PrsA according to the present invention includes a protein having an amino acid sequence represented by SEQ ID No. 2 and functional equivalents of the protein. The "functional equivalents" refer to proteins that have at least 30%, preferably, 40%, and more preferably, 50% sequence homology with the amino acid sequence represented by SEQ ID No. 2 as a result of addition, substitution, or deletion of amino acids, and exhibit substantially the same physiological activity as the protein represented by SEQ ID No. 2. The "substantially the same physiological activity" refers to the activity of displaying a target protein on the cell surface. It is unpredictable as to which amino acids could be removed and which could be added. While it is known that many amino acid substitutions are possible in any given protein, the position within the protein’s sequence where amino acid substitutions can be made with a reasonable expectation of success are limited. Other positions are critical to the protein’s structure/function relationship, e.g., such as various positions or regions directly involved in binding, catalysis in providing the correct three-dimensional spatial orientation of binding and catalytic sites. These regions can tolerate only very little or no substitutions. Selective point mutation to one key residue could eliminate the function of the polypeptide. It could eliminate its functional properties. If the range of decreased binding ability after single point mutation of a protein antigen varies, one could expect point mutations in the protein antigen to cause varying degrees of loss of protection/function, depending on the relative importance to the binding interaction of the altered residue. Alternatively, the combined effects of multiple changes, as instantly claimed, in an antigenic determinant could again result in loss of function. A protein having multiple point mutations, or accumulated point mutations at key residues could create a new antigen that is precipitously or progressively unrecognizable. As stated above, Applicants have not shown the particular substitution and the result it produces. Applicants have provided no guidance to enable one of ordinary skill in the art how to determine, without undue experimentation, the effects of different amino substitutions and the nature and extent of the changes that can be made. It is expensive and time consuming to make amino acid substitutions at more than one position, in a particular region of the protein, in view of the many fold possibilities for change in structure and the uncertainty as to what utility will be possessed. See Mikayama et al. (Nov.1993. Proc.Natl.Acad.Sci. USA, vol. 90 : 10056-10060) which teaches that the three-dimensional structure of molecules is important for their biological function and even a single amino acid difference may account for markedly different biological activities. Rudinger et al. (June 1976. Peptide Hormones. Biol.Council. pages 5-7) also teaches that amino acids owe their ‘significance’ to their inclusion in a pattern which is directly involved in recognition by, and binding to, the receptor and the significance of the particular amino acids and sequences for different amino acids cannot be predicted a priori, but must be determined from case to case by painstaking experimental study. The instant claims allow for substitutions with amino acids of vastly different properties, and they do not recite the specific changes in the claims. The specification is not enabled for the use of any microorganism as a host cell. Paragraph [50] recites: In the present invention, the microorganism is preferably lactic acid bacteria, and more preferably, lactic acid bacteria of the genus Lactobacillus, but the present invention is not limited thereto. The examples in the specification use a Lactobacillus paracasei strain. Paragraph [10] teaches that the reporter protein when used in a vector was displayed on the cell surface in all lactic acid bacteria transformed with a vector containing the coding sequence of the PrsA protein or its variants as defined in claims 2-4. It is unpredictable for the use of a virus or fungi, etc. Genentech Inc. v. Novo Nordisk A/S (CAFC) 42 USPQ2d 1001 clearly states: “Patent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable. See Brenner v. Manson, 383 U.S. 519, 536, 148 USPQ 689, 696 (1966) (stating, in context of the utility requirement, that "a patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion.") Tossing out the mere germ of an idea does not constitute enabling disclosure. While every aspect of a generic claim certainly need not have been carried out by an inventor, or exemplified in the specification, reasonable detail must be provided in order to enable members of the public to understand and carry out the invention.” The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims. Allowable Subject Matter Claims 2-4 are objected to as being dependent upon a rejected base claim but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Closest prior art: Chaillou et al (Nat. Biotechnol. 23:1527-1533(2005). "The complete genome sequence of the meat-borne lactic acid bacterium Lactobacillus sakei 23K.” 100% identical to SEQ ID NO: 2 ; FOLDASE PROTEIN PRSA/EPTIDYLPROLYL ISOMERASE; Accession No. Q38XZ9; KIM. J.-H. et al. Development and characterization of membrane surface display system using molecular chaperon, prsA, of Bacillus subtilis. Biochemical and Biophysical Research Communications. 2005, vol. 334, pp. 1248-1253 Claim 1 differs from Kim et al in terms of comprising: a PrsA promoter consisting of a nucleotide sequence of SEQ ID NO: 3; and a polynucleotide encoding PrsA consisting of an amino acid sequence of SEQ ID NO: 2. It is also from a different Genus/species of bacteria and does not teach these sequences. Chaillou teaches the complete genome of L.sakei. Correspondence regarding this application should be directed to Group Art Unit 1645. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Remsen. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15,1989). The Group 1645 Fax number is 571-273-8300 which is able to receive transmissions 24 hours/day, 7 days/week. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer E. Graser whose telephone number is (571) 272-0858. The examiner can normally be reached on Monday-Friday from 8:00 AM-4 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thomas Visone, can be reached on (571) 270-0684. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (571) 272-0500. /JENNIFER E GRASER/Primary Examiner, Art Unit 1645 10/20/26
Read full office action

Prosecution Timeline

Apr 16, 2025
Application Filed
Oct 23, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12782359
Plasmid For Bacillus Expressing Fluorescent Reporter Genes
4y 3m to grant Granted Nov 03, 2026
Patent 12778993
Bifidobacterium animalis in enriching organic zinc to promote growth and reproductive development
2y 6m to grant Granted Nov 03, 2026
Patent 12773448
COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS OF USE THEREOF
2y 2m to grant Granted Oct 27, 2026
Patent 12761222
METHODS AND COMPOSITIONS USING EXTRACELLULAR VESICLES FOR THE DETECTION OF DISEASE AND DISORDERS
4y 12m to grant Granted Oct 13, 2026
Patent 12760336
METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ACETYL-COA DERIVED PRODUCTS
3y 8m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
99%
With Interview (+23.2%)
2y 5m (~10m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1054 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month